The clinical and pharmacoeconomic analysis of invasive aspergillosis in adult patients with haematological diseases

Mycoses

Volumn 51, Issue 4, 2008, Pages 328-335

  Cagatay, A Atahan ^a,c   Cosan, F ^a   Karadeniz, A ^a   Besisik, S K ^b   Ozsut, H ^a   Nalcaci, M ^b   Pekcelen, Y ^b   Eraksoy, H ^a   Dincol, G ^b   Calangu, S ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Amphotericin B; Caspofungin; Invasive aspergillosis; Pharmacoeconomic analysis

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; DRUG COST; DRUG SAFETY; FEMALE; FEVER; HEALTH CARE COST; HEMATOLOGIC DISEASE; HUMAN; HYPOKALEMIA; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STANDARDIZATION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG COSTS; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 44849129181     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2007.01483.x     Document Type: Article

References (43)

1. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003 102 : 827 33.
2. Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur J Cancer Care 2001 10 : 56 62.
3. Latge JB. The pathobiology of Aspergillus fumigatus. Trends Microbiol 2001 9 : 382 9.
4. Dismukes WE. Introduction to antifungal drugs. Clin Infect Dis 2000 30 : 653 7.
5. Harbarth S, Burke JP, Lloyd JF, Evans RS, Pestotnik SL, Samore MH. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002 15 : 35.
6. Jansen JP, Meis JF, Blijlevens NM, van't Wout JW. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin 2005 21 : 1535 46.
7. Lortholary O, Charlemagne A, Bastides F et al. A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. J Antimicrob Chemother 2004 54 : 456 64.
8. Wingard JR, Leather HL, Wood CA et al. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am J Health Syst Pharm 2007 64 : 637 43.
9. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health 2002 5 : 26 34.
10. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 1 : 34.
11. Antoniadou A, Dupont B. Lipid formulations of amphotericin B; where are we today? J Mycologie Medicale 2005 15 : 230 8.
12. Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant 2004 10 : 73 90.
13. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003 36 : 1445 57.
14. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005 18 : 163 94.
15. Singh N. Treatment of opportunistic mycoses: how long is long enough? Lancet Infect Dis 2003 3 : 703 8.
16. de Pauw BE, Patterson TF. Should the consensus guidelines' specific criteria for the diagnosis of invasive fungal infection be changed? Clin Infect Dis 2005 6 : 377 80.
17. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996 23 : 608 15.
18. Herbrecht R, Letscher V, Andres E, Cavalier A. Safety and efficacy of amphotericin B colloidal dispersion. Chemotherapy 1999 45 (Suppl. 1 67 76.
19. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002 35 : 359 66.
20. Herbrecht R, Auvrignon A, Andres E et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001 20 : 77 82.
21. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995 155 : 1093 8.
22. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001 32 : 358 66.
23. Pagano L, Ricci P, Montillo M et al. Localization of aspergillosis to the central nervous system among patients with acute leukemia: report of 14 cases. Gruppo Italiano Malattie Ematologiche dell'Adulto Infection Program. Clin Infect Dis 1996 23 : 628 30.
24. Subira M, Martino R, Franquet T et al. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica 2002 87 : 528 34.
25. Jantunen E, Salonen J, Juvonen E. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol 2004 73 : 174 8.
26. Leenders AC, Daenen S, Jansen RL et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998 103 : 205 12.
27. Gefter WB, Albelda SM, Talbot GH, Gerson SL, Cassileth PA, Miller WT. Invasive pulmonary aspergillosis and acute leukemia. Limitations in the diagnostic utility of the air crescent sign. Radiology 1985 157 : 605 10.
28. Markaryan A, Morozova I, Yu H, Kolattukudy PE. Purification and characterization of an elastinolytic metalloprotease from Aspergillus fumigatus and immunoelectron microscopic evidence of secretion of this enzyme by the fungus invading the murine lung. Infect Immun 1994 62 : 2149 57.
29. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001 19 : 253 9.
30. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 71.
31. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B or empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 351 : 1391 402.
32. Wei H, Hai W, Wanqing L. Clinical study on liposomal amphotericin B (AmBisome) in deep fungal infections in China. Mycoses 2003 46 : 24 28.
33. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001 22 : 686 93.
34. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven Aspergillosis. Clin Infect Dis 1999 29 : 1402 7.
35. Barrett JP, Vardulaki KA, Conlon C et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003 25 : 1295 320.
36. Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001 45 : 3487 96.
37. Rex JH, Walsh TJ. Estimating the true cost of amphotericin B. Clin Infect Dis 1999 29 : 1408 10.
38. Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000 18 : 2476 83.
39. Patterson TF. New agents for treatment of invasive aspergillosis. Clin Infect Dis 2002 35 : 367 9.
40. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001 33 : 641 7.
41. Persson U, Tennvall GR, Andersson S, Tyden G, Wettermark B. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconomics 1992 2 : 500 8.
42. Wenzel R, Del Favero A, Kibbler C et al. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J Antimicrob Chemother 2005 55 : 352 61.
43. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990 12 : 308 29.